These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29251661)

  • 1. New urate-lowing therapies.
    Abhishek A
    Curr Opin Rheumatol; 2018 Mar; 30(2):177-182. PubMed ID: 29251661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for gout.
    Edwards NL; So A
    Rheum Dis Clin North Am; 2014 May; 40(2):375-87. PubMed ID: 24703353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesinurad for the treatment of hyperuricaemia in people with gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2017 Dec; 18(17):1875-1881. PubMed ID: 29103339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New medications in development for the treatment of hyperuricemia of gout.
    Diaz-Torné C; Perez-Herrero N; Perez-Ruiz F
    Curr Opin Rheumatol; 2015 Mar; 27(2):164-9. PubMed ID: 25603039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
    Terkeltaub R; Saag KG; Goldfarb DS; Baumgartner S; Schechter BM; Valiyil R; Jalal D; Pillinger M; White WB
    Rheumatology (Oxford); 2019 Jan; 58(1):61-69. PubMed ID: 30124941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.
    Tausche AK; Alten R; Dalbeth N; Kopicko J; Fung M; Adler S; Bhakta N; Storgard C; Baumgartner S; Saag K
    Rheumatology (Oxford); 2017 Dec; 56(12):2170-2178. PubMed ID: 29029210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesinurad: First Global Approval.
    Hoy SM
    Drugs; 2016 Mar; 76(4):509-16. PubMed ID: 26861027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
    Cicero AFG; Fogacci F; Kuwabara M; Borghi C
    Medicina (Kaunas); 2021 Jan; 57(1):. PubMed ID: 33435164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
    Jansen TL; Perez-Ruiz F; Tausche AK; Richette P
    Clin Rheumatol; 2018 Dec; 37(12):3159-3165. PubMed ID: 30244431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel uricosurics.
    Bardin T; Richette P
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i42-i46. PubMed ID: 29272511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G; Panova E; Day R
    Drug Des Devel Ther; 2017; 11():3077-3081. PubMed ID: 29123379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG; Fitz-Patrick D; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; Becker MA
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
    Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.